Overview

(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis

Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Phase:
Phase 2
Details
Lead Sponsor:
Cogent Biosciences, Inc.